Drug Trial Radar · NCT03905694
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 22, 2019
Primary completion
Jun 29, 2020
Study completion Jul 26, 2024
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
Conditions
- Primary Hyperoxaluria
- Primary Hyperoxaluria Type 1 (PH1)
Interventions
LumasiranDrug
Lumasiran will be administered by subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6Time frame: Baseline to Month 6
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Lyon, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Haifa, Israel
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Nahariya, Israel
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.